Table 1.
Characteristics of patients and controls
| Patients (n = 36) | Controls (n = 76) | |||
|---|---|---|---|---|
| Baseline | Follow-up | Baseline | Follow-up | |
| Gender (n, women/men) | 8/28 | 8/28 | 29/47 | 29/47 |
| Age (year) | 39.4 | 44.4 | 41.1 | 47.5§ |
| Education (year) | 12.6 | NA | 14.0§ | NA |
| WAIS verbal IQ | 87.3 | NA | 103.0*** | NA |
| GAF | 49.2 | 48.3 | 87.3*** | 83.9*** |
| SANS composite score | 28.9 | 33.4 | NA | NA |
| SAPS composite score | 10.0 | 11.1 | NA | NA |
| Medication (mg, CPZ-equivalents) | 208.9 | 263.3 | NA | NA |
| Medication-no antipsychotics (n) | 4 | 5 | NA | NA |
| Medication-2nd gen antipsychotics (n) | 14 | 15 | NA | NA |
| Medication-1st gen antipsychotics (n) | 16 | 9 | NA | NA |
| Medication-1st and 2nd gen antipsychotics (n) | 2 | 7 | NA | NA |
NS not significant, NA not applicable or not assessed, WAIS Wechsler adult Intelligence Scales, IQ intelligent quotient, GAF Global Assessment of Functioning, SANS Scale for the Assessment of Negative Symptoms, SAPS Scale for the Assessment of Positive Symptoms, CPZ chlorpromazine, gen generation, NOS not otherwise specified. All values in mean (standard deviation) except for distribution of gender, diagnosis and medication
Missing data (patients/controls): Education (0/1), WAIS vocabulary (7/12), GAF baseline (0/2), GAF follow-up (0/7), SANS/SAPS baseline (8/NA)
§p < 0.1 ***p < 0.001